Biotechnology company Genmab A/S (CPH:GEN) declared on Tuesday that worldwide net sales of DARZALEX (daratumumab), as reported by Johnson & Johnson, were USD511m in the second quarter of 2018.

Out of these net sales, USD298m was in the US and USD213m was in the rest of the world. Genmab will receive royalties on the worldwide net sales of DARZALEX under the exclusive worldwide license to Janssen Biotech Inc to develop, manufacture and commercialise DARZALEX.

Daratumumab is being developed by Janssen Biotech Inc under an exclusive worldwide license to develop, manufacture and commercialise daratumumab from Genmab. A comprehensive clinical development programme for daratumumab is ongoing, including multiple phase III studies in smouldering, relapsed and frontline multiple myeloma settings and in amyloidosis.

Also, additional studies are ongoing or planned to assess the potential of daratumumab in other malignant and pre-malignant diseases, such as NKT-cell lymphoma, myelodysplastic syndromes, B and T-ALL.

Daratumumab has received two Breakthrough Therapy Designations from the US FDA, for multiple myeloma, as both a monotherapy and in combination with other therapies.

Genmab is specialising in the creation and development of differentiated antibody therapeutics for the treatment of cancer.